Amydis is the leader in developing a new class of diagnostic compounds that enable digital detection and monitoring of human disease-related molecular biomarkers through standard ocular imaging cameras. This pioneering technology can accelerate diagnosis, improve the clinical testing of novel therapeutics and revolutionize treatment. Retina as a Window to the Brain-The retina is part of the central nervous system (CNS) that can be conveniently imaged using high-resolution standard ocular imaging cameras. It provides an opportunity to detect signs of neurodegenerative diseases during a routine eye exam. The retina contains many of the neural, synaptic, and glial elements that are impacted in the brain by diseases such as amyotrophic lateral sclerosis (ALS), Parkinson’s and Alzheimer diseases. Most importantly, molecular biomarkers of these diseases, which present as deposits of abnormally folded proteins are found in the retina.. Amydis’ innovative technology provides the ability to perform a virtual biopsy via a simple eye exam and detect diseases at much earlier stages than is currently possible. Amydis shifts the diagnostic paradigm - At present, people at risk for developing neurodegenerative diseases do not seek medical attention until they are overtly symptomatic, a point at which irreversible damage has already occurred and a window of opportunity for therapeutics has greatly narrowed. An example of the impact of screening and early diagnosis is mammogram screening to detect the earliest stages of breast cancer. In neurodegenerative diseases, there are measurable indices of early disease manifested as deposits of abnormally folded proteins in CNS, but as of yet there have been no simple, convenient, and widely adoptable technologies to measure them. Our technology, by detecting biomarkers of neurodegeneration in retina, will shift diagnosis to an earlier and more broadly accessible point of care: the eye care specialists.